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We observed a young patient with slight mental retardation, suffering from drug-resistant tonic-clonic seizures, who presented 
a status epilepticus (SE), in two separate periods when valproic acid (VPA) was added to the phenobarbital (PB) already 
being used in the patient’s therapy. The VPA-induced SE was characterized by normal plasma levels of antiepileptic drugs 
(AEDs), normal ammonemia nd normal liver function. The case we studied represents the first report on a VPA-induced 
SE. Furthermore the case confirms that VPA, as well as causing encephalopathy secondary to hyperammonemia, may also 
provoke a primary involvement of the central nervous system (CNS), specially when used in young epileptic, mentally 
retarded subjects. In an attempt to explain the paradoxical effect of VPA we hypothesise that the SE could be due to an 
increase in excitatory activity producing a consequent epileptogenic effect in those subjects with a predisposition for toxic 
reaction to VPA therapy due to congenital anomalies of neural networks, 
Key words: valproate, encephalopathy, epileptic tonic status, excitotoxicity. 
INTRODUCTION 
The administration of valproic acid (VPA), an 
antiepileptic drug (AED) often used to control typ- 
ical absence seizures and generalized tonic-clonic 
seizures, is sometimes the cause of severe toxic 
effects which involve the central nervous system 
(CNS). Many reports emphasize the role of VPA in 
inducing an encephalopathy characterized by ataxia, 
stupor and coma***. 
In certain conditions VPA produces a paradox- 
ical effect by increasing the number of epileptic 
seizures3”. 
The most widely recognized hypothesis is that the 
encephalopathy is caused by an increase of ammone- 
mia, due to hepatic or renal dysfunction”“. 
In this study the case of a young epileptic patient is 
reported. The boy suffered a status epilepticus (SE), 
with normal plasma levels of the AED, normal am- 
monemia and normal liver function, in two different 
periods when VPA was added to phenobarbital (PB), 
already being used in therapy. 
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PATIENT REPORT 
The patient is a lCyear-old, right-handed boy af- 
fected by AED-resistant epileptic seizures. There 
were no familial neurological diseases, apart from 
a cousin of his mother who had generalized epilep- 
tic seizures during childhood and adolescence. The 
pregnancy, birth and psychomotor development were 
normal; until the appearance of the first seizure he 
had not been affected by any serious illnesses. 
The first generalized tonic-clonic seizure occurred 
at age 6 years; the second seizure appeared 3 months 
later, after which the boy started taking PB. He did 
not experience another seizure for 3 years. Between 
the ages of 9 and 14 years he presented repeated 
tonic-clonic seizures, averaging one every 3 months. 
During this period he was taking 100-150 mg of PB 
a day with plasma levels between 18 and 27 pg/ml. 
At the age of 14 years, after a period character- 
ized by frequent tonic-clonic seizures, he was ad- 
mitted to the Neurological Clinic of the University 
of Perugia. At the time of admission the neurologi- 
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cal examination was normal, the cognitive function 
evaluation showed a slight mental retardation and a 
cranial cerebral tomography (CT) scan did not show 
any alterations. 
In order to control the seizures VPA was associated 
to a daily PB dose of 4 mgkg with a plasma level of 
24 pg/ml. At first a daily VPA dose of 10 mgfkgfday 
was administered. This was progressively increased 
over 7 days to a maximum dose of 25 mg/kg/day 
in three administrations. Approximately 13 days af- 
ter the start of VPA the clinical picture worsened 
considerably. The boy started to have axorhizomelic 
tonic seizures that increased in number until SE was 
reached. 
After 2 days of these conditions, and before sus- 
pending VPA, the plasma levels of the AEDs were 
within the therapeutic range (PB 26, VPA 56 and 69 
on an empty stomach and 3 hours after the first ad- 
ministration respectively). 
The suspension of VPA led to the complete regres- 
sion of the tonic seizures in a few days. The boy was 
discharged with a monotherapy of PB. 
Three months later, during another period in hos- 
pital because of persistent tonic-clonic seizures, VPA 
was added to PB following the same procedure of a 
progressive increase until a maximum dosage of 25 
mg/kg/day was reached. Fifteen days after the start 
of this new trial the boy again suffered several tonic 
epileptic seizures with the same characteristics as the 
previous episode. The AED plasma levels, as before, 
were within the therapeutic range, 64 and 70 kg for 
VPA and 31 pg for PB. 
The epileptic tonic status disappeared completely 
in the 5 days following the suspension of VPA. 
Electroencephalography studies 
The boy periodically underwent electroencephalo- 
graphs (EEGs) from the age of 6 years, a few months 
after the appearance of the first seizure. 
lnterictal EEGs 
At age 6 and 7 years the EEG showed posterior 9 
Hz alpha-rhythm background activity, several poste- 
rior slow waves and bilateral, synchronous and sym- 
metric subclinical short spike and wave discharges at 
3-4 Hz (Fig. 1). The EEGs, performed from age 8 to 
14 years, showed the same background activity and 
the same intercritical, paroxysmal anomalies. 
Electroclinical findings of status epilepticus 
Throughout both the first and the second therapeutic 
trial with a VPA-PB association, the boy presented 
a SE expressed by very frequent, short and long ax- 
orhizomelic tonic seizures. 
The short axorhizomelic seizures, lasting only 2-5 
seconds, were more frequent and mainly involved the 
face, neck and upper limb muscles. The less frequent 
long axorhizomelic seizures, lasting 15-20 seconds, 
began in the neck and face muscles and rapidly in- 
volved the upper and lower limbs. 
As far as the EEG is concerned, in a high-voltage 
delta background activity, interrupted by isolated 
spikes and sharp waves on all the derivations, the 
short tonic seizures (Fig. 2) were characterized by 
the sudden appearance of a generalized, very rapid, 
high amplitude activity at about 20 Hz. 
In the same background activity, the axorhizomelic 
long seizures (Fig. 3) appeared initially with a sudden 
flattening of all electrical activity corresponding to the 
involvement of the axial muscles, followed by rapid 
activity, increasing in amplitude on all the deriva- 
tions, corresponding to tonic involvement of the limb 
muscles. 
Metabolic parameters 
During both the first and the second tonic SE, many 
biochemical parameters were evaluated: serum glu- 
cose, blood urea nitrogen, prothrombine time, GOT, 
GPT, )/GT, alkaline phosphatase, CPK, LDH and 
biliary acids. All the values were found to be nor- 
mal. At the same time ammonemia monitoring was 
also performed. During the first trial ammonemia 
reached maximum values of 38 Fg/dl, while in the 
second trial it remained between minimum values of 
20 kg/d1 and maximum values of 31 Fg/dl (normal 
values less than 75 pg/dl). 
DISCUSSION 
In our report we described a case of SE elicited 
by VPA. Various AEDs can result in an increase in 
epileptic seizures or elicit new types of seizure1 I. It 
has already been shown that VPA in particular con- 
ditions could worsen epileptic seizures. 
Dreifuss et al4 described a SE, attributed to VPA- 
induced hepatotoxicity, in some patients undertaking 
VPA therapy associated with other AEDs. Bohan et 
al5 reported a SE and liver damage in an epileptic 
child treated with valproate. An unexplainable ab- 
sence status was reported by Jeavons et al3 in five 
patients taking an association of VPA-clonazepam. 
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Fig. 1: EEG, recorded at the age of 8 years, showing interictal, generalized, spike and wave discharges at 3-4 Hz. 
Fig. 2: VPA-PB tonic SE: several, short, axorhizomaelic seizures characterized by generalized, very rapid, high amplitude activity 
at about 20 Hz. 
The VPA-induced increase of epileptic seizures has 
been related to hyperammonemia with or without 
hepatic damage. 
During VPA therapy, some young, metabolically 
susceptible patients could present hyperammonemia 
and hepatic lesions”, necrosis and microvescicular 
steatosis, caused by an error of the mytochondrial l3- 
oxidation . I3 Valproic-acid-’ Induced hyperammonemia 
without hepatic damage could be explained by an in- 
crease of propionate in the blood, which inhibits the 
carbamyl phosphate synthetase I activity, leading to 
an increase of ammonium’“. An alternative hypoth- 
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Fig. 3: VPA-PI3 tonic SE: long-lasting, axorhizomaelic seizures, showing initial flattening of electrical activity (involvemer 
mus cles), followed by rapid activity increasing in amplitude (tonic involvement of limb muscles). 
esis is that the VPA-induced increase of renal glu- 
taminase activity is responsible for the increase of 
ammonium in the renal vascular system and in the 
genera1 artery system which is too great for the liver 
to correct’5. 
Other studies have demonstrated that VPA can pro- 
duce a primary involvement of the CNS. Sackellares 
et ~1’~ demonstrated in four epileptic patients that 
the stupor induced by VPA, in association with other 
AEDs, was accompanied by normal ammonemia and 
normal liver-function values. Pakalnis et a/l7 indi- 
cated that in some young epileptics, showing slight 
or mild mental retardation, the addition of VPA to 
pre-existing AEDs was the cause of an acute en- 
cephalopathy without signs of hepatic dysfunction, 
with normal ammonemia and plasma levels of AEDs 
in the therapeutic range. 
The case we have described is the first report re- 
vealing that VPA could induce a SE without hyper- 
ammonemia or hepatic damage. 
The young patient showed slight mental retardation 
and suffered from generalized epilepsy expressed by 
tonic-clonic seizures that were not controlled by the 
therapy. 
The clinical-EEG characteristics of VPA-induced 
SE, the value of ammonium (checked several times) 
below pathological levels and the absence of any 
marker of hepatic damage, lead us to believe that 
VPA was the cause of a primary involvement of the 
CNS. 
It of axial 
The action mechanism of VPA is still unclear. Val- 
proic acid seems to increase the levels of GABA 
in the CNS by inhibition of y-aminobutyric acid 
(GABA) degradation’* and may increase the GABA 
postsynaptic responses. Furthermore the mechanism 
through which the VPA as well as other AED- 
exacerbate seizures is unknown’ ’ . 
Several hypotheses have been proposed to ex- 
plain the paradoxical effect of VPA involving 
GABA”* ‘9-2’ or excitatory aminoacids (EAA)22,23 
transmission. 
This drug could induce an increase of the excita- 
tory transmission in some mentally retarded subjects 
with possible congenital anomalies of complex neural 
networks. 
The increased activation of EAA receptors, partic- 
ularly n-methyl-d-aspartate NMDA, could lead to an 
excitotoxic and epileptogenic effect. 
It seems that mental retardation may play an im- 
portant role in SE induction in the presence of VPA 
therapy. Both in our case and in those described by 
Pakalnis”, metabolic, enzymatic and malformative 
disorders that could confirm the hypothesis of a pre- 
disposition for a toxic reaction to VPA therapy have 
not been found. 
Further studies of the molecular involvement of 
mental retardation and molecular modifications of the 
receptors are being carried out24 and, in the future, 
we should be able to explain the mechanisms that are 
still unclear. 
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